News & Events
-
Watch HOPE Summit 2026 Videos
HOPE Summit 2026 was filled with old friends reuniting, new friends being made, and of course, plenty of inspirational and informative sessions designed to help people live well with lung cancer.
For...
-
Clinical Trial Access Isn’t Expanding. It’s Concentrating.
Clinical trials show us whether a new treatment is safe and effective. They are also an important way for patients to access cutting-edge care. For trials to truly serve the lung... -
Podcast: Lung Cancer Diagnosis—What Happens Next
What happens after a lung cancer diagnosis? In this first episode of LUNGevity’s Lung Cancer Voices of Hope podcast, lung cancer survivor Lisa Bistline shares her experience, from... -
Podcast: Why Community Matters in Lung Cancer Care
Why does finding community matter in lung cancer care? In this episode, lung cancer survivor and advocate Jill Feldman shares her experience, from losing multiple family members to... -
Scalp Care, Shaving, and Head Coverings: Comfort Through Hair Loss
This video is a recording from a LUNGevity virtual meetup. Each month, we host multiple virtual meetups for those impacted by lung cancer to meet and connect with others who... -
Meet The “Mini-Organs” of Lung Cancer Research
Though many of us would like to deny it, our neighbors affect us. Their loud music disturbs our sleep. The scent of their dinner wafts through an open window. The sight of their... -
Three Moments That Defined the 2026 Targeted Therapies of Lung Cancer Conference
The 2026 Targeted Therapies of Lung Cancer Meeting brought together leading clinicians, researchers, and patient advocates to discuss the latest advances shaping the future of lung... -
Progress in Cancer Care: What the Numbers Tell Us About Lung Cancer
Every January, the American Cancer Society releases a Cancer Facts & Figures report. It provides a clear view of where we stand in addressing cancer. The 2026 report brings both... -
KRAS Virtual Meetup
Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. After registering, you will receive a confirmation email... -
Why Immunotherapy Isn’t Perfect & How Scientists Are Working to Fix It
The human immune system is an intricate web of checks and balances that usually excels at detecting and destroying foreign invaders, such as bacteria and viruses, while protecting...
KRAS Q61-Mutant NSCLC Shows Distinct Molecular Patterns and Better Outcomes With Immunotherapy-Based Regimens
KRAS Q61-Mutant NSCLC Shows Distinct Molecular Patterns and Better Outcomes With Immunotherapy-Based Regimens
Design and evaluation of KRAS-targeting heteroaromatic thiosemicarbazone scaffolds for lung cancer: an integrated molecular docking, DFT calculations, and preclinical study
Design and evaluation of KRAS-targeting heteroaromatic thiosemicarbazone scaffolds for lung cancer: an integrated molecular docking, DFT calculations, and preclinical study
Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies
Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies
New antibody may boost KRAS-targeted lung cancer treatment after resistance emerges
New antibody may boost KRAS-targeted lung cancer treatment after resistance emerges
Clinical Trial: Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
Clinical Trial: Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC
U.S. Clinical Trial: UNC Lineberger Comprehensive Cancer Center Listed a New Clinical Trial to Study Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally...
U.S. Clinical Trial: UNC Lineberger Comprehensive Cancer Center Listed a New Clinical Trial to Study Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally...
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses Available
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses Available
小分子KRAS G12D抑制剂获积极临床进展；针对多种实体瘤，创新ADC展现治疗潜力…… | 一周盘点_腾讯新闻
GFH375/VS-7375 Granted with FDA's Fast Track Designation for Treatment of KRAS G12D-mutant Unresectable Locally Advanced or Metastatic NSCLC
GFH375/VS-7375 Granted with FDA's Fast Track Designation for Treatment of KRAS G12D-mutant Unresectable Locally Advanced or Metastatic NSCLC